We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Reveals that a Th17 signature predicts dual checkpoint inhibitor efficacy in metastatic renal cell carcinoma, highlighting a biomarker for patient stratification.
No takes yet. Share an insight, caveat, or question.
Guglietta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: